BnR Summit 2026

Belt & Road Summit - Deal-Making 2026

9 – 15 Sept 2026 | Hong Kong, China (Hong Kong)

Register
Register
Register

ProjectUpdated on 3 August 2026

Point-of-care Early Cancer Breath Testing

Founder & CEO at Qi Diagnostics Limited

China (Hong Kong)

About

We are proud to be the first team to develop a cancer-specific breath marker and a POC breathalyzer device with high sensitivity and promising clinical applicability in detecting cancer tumors.

Our clinical studies have demonstrated the detection of early stage 0–I microinvasive lung adenocarcinoma that screens out higher risk patients for prioritized follow up and better utilize the limited medical resources in the hospital. Also, real-time cancer treatment response monitoring that can flag progression ahead of imaging addition to how doctors monitor patients in routine practice.

Project Location

  • China (Hong Kong)

Project Format

  • Private Project

Go Global Project

  • Yes

ESG (Environmental, Social, and Governance)

  • No

Project Stage

  • Investment / Financing Discussion

Main Project Sector

  • Technology

Technology

  • Health Technology
  • Medical Technology

Investment Capital Required

  • 2,500,001 to 5,000,000 USD

Interested Format of Cooperation

  • Convertible Loan
  • Direct Equity Investment
  • Minority Shareholdings
  • Open for Negotiation

Preferred Financing Model

  • Debt
  • Equity
  • Public / Alternative Financing
  • Open for negotiation

Type(s) of Last Financing Round of the project (if Applicable)

  • Equity (private)

Main Service(s) Required

  • Financial Services

Financial Services

  • Institutional Investment
  • Private Equity & Venture Capital

Organisation

Qi Diagnostics Limited

China (Hong Kong)

Similar opportunities